VYRIAD Trademark

Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable genetic diseases; pharmaceutical preparations for treatment of genetic and heritable genetic diseases; cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical preparations for use in oncology; all of the foregoing to exclude infectious diseases

Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells (CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases